Kazutoshi Watanabe

Yokohama, 2270033, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Evaluation of scattered radiation from fluoroscopy using small OSL dosimeters.

Evaluation of scattered radiation from fluoroscopy using small OSL dosimeters.

Journal: Radiological physics and technology

Published: April 01, 2019

Edaravone and its clinical development for amyotrophic lateral sclerosis.

Edaravone and its clinical development for amyotrophic lateral sclerosis.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: September 06, 2017

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Journal: Journal of clinical biochemistry and nutrition

Published: June 30, 2017

Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.

Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: March 29, 2017

Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.

Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: March 29, 2017

Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease.

Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease.

Journal: Bioorganic & medicinal chemistry letters

Published: October 16, 2014

Asymmetric synthesis of 2-arylpiperazines.

Asymmetric synthesis of 2-arylpiperazines.

Journal: Bioorganic & medicinal chemistry letters

Published: September 22, 2014

2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors.

2-(2-Phenylmorpholin-4-yl)pyrimidin-4(3H)-ones; a new class of potent, selective and orally active glycogen synthase kinase-3β inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 23, 2013

6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.

6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 23, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026